<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607217</url>
  </required_header>
  <id_info>
    <org_study_id>SBMU- 86-03-105-5433B</org_study_id>
    <secondary_id>SMMC- 13861008B</secondary_id>
    <nct_id>NCT00607217</nct_id>
  </id_info>
  <brief_title>The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases</brief_title>
  <official_title>Controlled Trial of Serologic and Clinical Efficacy of Influenza Vaccine in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study wishes to understand:

        1. whether vaccination against influenza in coronary artery disease (myocardial infarction
           and stable angina) patients is as effective as it is in healthy subjects;

        2. whether vaccination really decreases the episodes of influenza infection in those
           coronary artery disease patients who receive the vaccine than those who do not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza infection may become complicated in patients with chronic conditions, including
      coronary artery disease (CAD) [1]. Influenza vaccination is now recommended as part of
      comprehensive secondary prevention in individuals with coronary and other atherosclerotic
      vascular disease (evidence level: Class I, Level B) [2]. Although there is controversial
      evidence pro [3,4] and against [5] the efficacy of influenza vaccination in protecting CAD
      population against cardiovascular events, the efficacy of vaccine in actual reduction in
      episodes of influenza infection and its fatal complications in CAD patients has not been, to
      our knowledge, well studied before. Furthermore, we found no report comparing serologic
      response to the influenza vaccine antigens between CAD patients and healthy controls.

      This study aims to identify the efficacy of influenza vaccination in CAD individuals in terms
      of both serologic response (as compared with healthy individuals) and clinical outcomes (as
      compared with CAD patients not vaccinated).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influenza infection</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serologic response (≥4-fold HI titer rise) to each of the 3 antigens of the trivalent vaccine of the 2006-07 campaign [Solomon Islands/3/2006(H1N1), Wisconsin/67/2005 (H3N2), and Malaysia/2506/2004 - like strains]</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of change in the antibody titer against each of the three influenza vaccine antigens</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protective antibody (≥1:40) titer after vaccination</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza-related death</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Coronary Artery Diseases</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>CAD-Exp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled coronary artery disease patients who are randomly assigned to receive influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAD-Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Enrolled coronary artery disease patients who are randomly assigned to receive placebo of influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy-Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled healthy subjects serve as control for CAD-Exp</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza vaccine</intervention_name>
    <description>Intramuscular injection of one 0.5-mL dose of influenza vaccine</description>
    <arm_group_label>CAD-Exp</arm_group_label>
    <other_name>2006-2007 vaccination campaign of Influvac (SolvayPharma)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo for influenza vaccine</intervention_name>
    <description>Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine</description>
    <arm_group_label>CAD-Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza vaccine</intervention_name>
    <description>Intramuscular injection of one 0.5-mL dose of influenza vaccine</description>
    <arm_group_label>Healthy-Control</arm_group_label>
    <other_name>2006-2007 vaccination campaign of Influvac (SolvayPharma)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary artery disease (CAD) group (CAD-Exp and CAD-Control):

          -  Patients with the diagnosis of acute, evolving or recent MI (after recovered the acute
             phase) as defined by:

             1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of
             biochemical markers of myocardial necrosis with at least one of the following:

          -  Ischemic symptoms

          -  Development of pathologic Qwaves on the ECG

          -  ECG changes indicative of ischemia (ST segment elevation or depression); OR

          -  Coronary artery intervention (e.g., coronary angioplasty). 2. Pathologic findings of
             an acute MI [1]:

          -  Patients with stable angina pectoris (SA) and documented coronary artery stenosis
             (angiography).

          -  Healthy Control group: healthy controls, proportionally matched by gender and age with
             the patient group (separate control groups for MI and SA patients).

        Exclusion Criteria:

          -  Any acute disease

          -  Chronic liver or kidney diseases

          -  Conditions accompanied by immunosuppression (like organ transplantation, HIV)

          -  Diagnosed malignancy

          -  Incubation with influenza vaccine within the past 5 years

          -  Any psychological disease that interferes with regular follow-up

          -  Congestive heart failure (Killip class IV)

          -  Unstable angina; AND

          -  Contradictions of vaccine incubation (like egg allergy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryam Keshtkar-Jahromi, M.D.; M.P.H.</last_name>
    <role>Study Chair</role>
    <affiliation>Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossein Vakili, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Research Center, Shaheed Beheshti Medical University, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Rahnavardi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Eskandari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaheed Beheshti University (MC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharareh Gholamin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaheed Beheshti University (MC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyed Mostafa Razavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaheed Beheshti University (MC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shaheed Modarres Medical Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA. 2004 Sep 15;292(11):1333-40.</citation>
    <PMID>15367555</PMID>
  </reference>
  <reference>
    <citation>Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 May 16;113(19):2363-72. Erratum in: Circulation. 2006 Jun 6;113(22):e847.</citation>
    <PMID>16702489</PMID>
  </reference>
  <reference>
    <citation>Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002 May 7;105(18):2143-7.</citation>
    <PMID>11994246</PMID>
  </reference>
  <reference>
    <citation>León de la Fuente R, Gurfinkel EP, Toledo D, Mautner B; Grupo de Estudio FLUVACS. [Flu vaccination in patients with acute coronary syndromes: treatment benefit in prespecified subgroups]. Rev Esp Cardiol. 2003 Oct;56(10):949-54. Spanish.</citation>
    <PMID>14563288</PMID>
  </reference>
  <reference>
    <citation>Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, Thompson WW; Vaccine Safety Datalink Study Group. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol. 2002 Oct 1;156(7):634-40.</citation>
    <PMID>12244032</PMID>
  </reference>
  <reference>
    <citation>Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000 Sep;36(3):959-69. Erratum in: J Am Coll Cardiol 2001 Mar 1;37(3):973.</citation>
    <PMID>10987628</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <last_update_submitted>January 20, 2009</last_update_submitted>
  <last_update_submitted_qc>January 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Maryam Keshtkar-Jahromi</name_title>
    <organization>Infectious Diseases and Tropical Medicine Research Center, SBMU, Tehran, Iran</organization>
  </responsible_party>
  <keyword>Coronary artery diseases</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Stable angina</keyword>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

